Impulse from radiotherapeutics confirms accelerated growth of nuclear medicine

MEDraysintell releases its new Nuclear Medicine World Market Report and Directory–Edition 2017, a 1,100-page document that provides an exhaustive description and analysis of more than 390 products, including over 140 radiopharmaceuticals under clinical development, with a comprehensive profile of 193 companies and institutions active in the radiopharmaceuticals industry.

Detailed table of contents and sample pages available upon request a peg@medraysintell.com

MEDraysintell estimates that the global market for nuclear medicine reached US$ 4.5 billion in 2016, growing by almost 5% from 2015. The market is expected to reach US$ 26 billion in 2030, a little higher than expected a year ago, with radiotherapeutics to represent 60% of the nuclear medicine market by 2030 compared to 12% in 2016.

During the last year we observed again an increasing interest from private investors and conventional pharmaceutical industries for the nuclear medicine market, of course mainly in the therapeutic area. This led also to some major M&A activities, such as the acquisition of Mallinckrodt Nuclear Medicine by IBA Molecular in April 2017 which led to the creation of a new entity named Curium. Over the same period Jubilant Draximage acquired Triad Isotopes and Sofie Biosciences took over Zevacor Pharma. Several small companies came to the surface of nuclear medicine with new approaches in the development of radiotherapeutics and radiotheranostics. Additional quite large investments were made by conventional pharmaceutical funds in small startups specialized in radiotherapeutics.

All these topics and much more are extensively covered in the new Nuclear Medicine Report & Directory, Edition 2017. This fourth edition will once again advice the radiopharmaceutical industry, investment organizations, international consulting firms, R&D laboratories to understand the market, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A) in this field.

More information and a table of contents are available at:
http://medraysintell.com/Nuclear_Medicine.html

About MEDraysintell
Strategic intelligence for the radiation healthcare
Bringing value to Businesses and Investors!

MEDraysintell is a team of international experts providing first-rate strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy. We offer the most comprehensive set of reports and directories, written by specialists from the field, with over 2,100 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment. We offer client-specific intelligence in the field of radiation healthcare, with the upmost knowledge leveraging our extended network of worldwide contacts. We are proud to support numerous companies globally, helping them better understand the markets, the competitive environment, the technology development as well as the potential of merger and acquisitions (M&A). We have repeat satisfied clients operating in the field of medical radiation, investment banks and institutional investors, large international consulting firms and universities research laboratories. MEDraysintell was created in 2013 by Paul-Emmanuel Goethals and Richard Zimmermann. It combines over 40 years of experience in radiation healthcare. www.medraysintell.com

MEDraysintell
Chemin du Cyclotron 6
1348 Louvain-la-Neuve, Belgium
Paul-Emmanuel Goethals, MBA
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

This release was published on openPR.